Literature DB >> 19013746

Lower uterine segment involvement is associated with adverse outcome in patients with stage I endometroid endometrial cancer: results of a multicenter study.

O Gemer1, M Gdalevich, M Voldarsky, F Barak, A Ben Arie, D Schneider, T Levy, E Y Anteby, O Lavie.   

Abstract

OBJECTIVE: To quantify the relative risk associated with lower uterine segment involvement (LUSI) on outcome measures in patients with apparent stage I endometroid endometrial cancer.
METHODS: A cohort of 769 consecutive patients with endometroid endometrial carcinoma apparent stage I, who underwent surgery in five gynecological oncology centers in Israel; 138 patients with and 631 without LUSI were followed for a median time of 51 months. Local recurrence, recurrence-free and overall survival were compared between the two groups.
RESULTS: LUSI was associated with grade 3 tumor (p=0.002), deep myometrial invasion (p<0.001), and the presence of lymphvascular space involvement (p=0.01). There were 22 cases of local recurrences, 40 cases of distal recurrences and 80 patients died. Univariate survival analysis showed that patients with LUSI had trend toward lower regional recurrence-free survival (p=0.09), and significant lower distant recurrence-free survival (p=0.04) and lower overall survival (p=0.002). The Cox proportional hazards model demonstrated a significantly decreased overall survival (HR=2.3; 95% CI 1.3, 3.9; p=0.003) in cases with LUSI.
CONCLUSIONS: In patients with apparent stage I endometroid endometrial cancer, the presence of LUSI is a poor prognostic factor, associated with a significantly higher risk of distal recurrence and death. The presence of LUSI warrants consideration when deciding upon surgical staging or postoperative management.

Entities:  

Mesh:

Year:  2008        PMID: 19013746     DOI: 10.1016/j.ejso.2008.10.007

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  2 in total

1.  Lower uterine segment involvement is associated with poor outcomes in early-stage endometrioid endometrial carcinoma.

Authors:  Nora T Kizer; Feng Gao; Saketh Guntupalli; Premal H Thaker; Matthew A Powell; Paul J Goodfellow; David G Mutch; Israel Zighelboim
Journal:  Ann Surg Oncol       Date:  2010-12-22       Impact factor: 5.344

2.  Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors.

Authors:  Liron Kogan; David Octeau; Zainab Amajoud; Jeremie Abitbol; Ido Laskov; Alex Ferenczy; Manuela Pelmus; Neta Eisenberg; Roy Kessous; Susie Lau; Amber Yasmeen; Walter H Gotlieb; Shannon Salvador
Journal:  Gynecol Oncol Rep       Date:  2018-03-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.